Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing. The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place. Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
